

































	 Ulipristal	 acetate	 is	 a	 new	 synthetic	 selective	 progesterone	 receptor	modulator	 developed
mainly	as	emergency	contraceptive	(EC)	and	also	used	for	the	treatment	of	uterine	fibroids.
A	cost	effective,	sensitive,	simple	and	rapid	high	performance	liquid	chromatography‐tandem
mass	 spectrometry	 (LC‐MS/MS)	 method	 was	 developed	 and	 validated	 for	 the	 analysis	 of
ulipristal	acetate	in	human	plasma.	Following	liquid‐liquid	extraction,	the	analyte	(Ulipristal
acetate)	and	internal	standard	(Levonorgestrel)	were	chromatographed	using	mobile	phase
in	 an	 isocratic	 elution	 mode	 on	 a	 reverse	 phase	 C18	 column.	 The	 LC‐MS/MS	 operated	 in
multiple	reaction	monitoring	mode	for	respective	[M+H]+	ions,	m/z	476.2/134.1	for	analyte
and	313.3/245.1	 for	 internal	 standard.	The	assay	 exhibited	 linear	dynamic	 range	of	1‐300



















or	 contraceptive	 failure.	 Emergency	 contraception	 is	 defined	
as	the	use	of	any	drug	or	device	after	unprotected	intercourse	
to	 prevent	 an	 unwanted	 pregnancy.	 Ulipristal	 acetate	 is	 a	
derivative	of	19‐norprogesterone	and	was	developed	 to	have	
enhanced	 specificity	 for	 progesterone	 receptor.	 Pre‐clinical	
studies	 indicate	 that	 ulipristal	 acetate	 (UPA)	binds	 to	human	
progesterone,	 glucocorticoid	 and	 androgen	 receptors	 at	 app‐
roximately	6,	1.5	and	0.2	times	the	affinity	of	the	endogenous	
ligands	 and	 shows	 in‐vivo	 anti‐glucocorticoid	 and	 anti‐
androgen	activity	at	doses	approximately	50‐fold	greater	than	









by	 progesterone	was	 blocked,	 and	 the	 proteins	 necessary	 to	
begin	 and	 maintain	 pregnancy	 are	 not	 synthesized	 [4].	
Ulipristal	 acetate	5	mg	dose	 is	also	used	 for	 the	 treatment	of	
uterine	 fibroids	 due	 to	 its	 safety	 and	 efficacy	 [5].	 Following	
oral	 administration	 ulipristal	 acetate	 rapidly	 absorbed	 with	
peak	 plasma	 concentration	 of	 176±89	 ng/mL,	 and	 was	
extensively	metabolized	by	CYP3A4	 in	 liver	and	 the	principal	
metabolites	formed	are	mono	and	di	demethylated	derivatives,	
of	 which	 mono	 demethylated	 derivative	 was	 pharmacolo‐
gically	active	 [6].	The	measurement	of	ulipristal	acetate	 itself	
would	suffice	for	bioequivalence	and	pharmacokinetic	studies	
that	 support	 for	 regulatory	 submissions	 in	 commercial	 envi‐
ronment.	In	literature	HPLC	method	was	reported	[7]	and	LC‐
MS/MS	methods	used	in	some	clinical	trials	were	reported	for	
determination	 of	 ulipristal	 acetate	 [5,8],	 to	 the	 best	 of	 our	
knowledge	 no	 specific	 LC‐MS/MS	 method	 was	 published	 till	
today	 for	 analysis	 of	 ulipristal	 acetate	 in	 human	 plasma.	 In	
present	 study,	 optimized	 chromatographic	 conditions	 were	

















The	 ulipristal	 acetate	 reference	 standard	 and	 internal	
standard	 (ISTD;	 levonorgestrel)	 were	 obtained	 from	 Clear‐
synth	 Labs.	 Mumbai,	 India.	 Gradient	 grade	 LiChro‐solv	
methanol,	 acetonitrile	 (ACN),	 analytical	 grade	 ammonium	
formate,	 sodium	 carbonate	 and	 formic	 acid	 (GR	 grade)	were	
purchased	 from	 Merck	 specialities	 (Mumbai,	 India).	 Methyl	
tert‐butyl	 ether	 and	 n‐hexane	were	 purchased	 from	 Rankem	
(Mumbai,	 India).	 Ultrapure	 type‐1	water	 from	Milli‐Q	 system	
(Millipore,	Bedford,	MA,	USA)	was	used	for	all	preparations	in	
the	study.	Polypropylene	RIA	vials	(ABDOS,	New	Delhi,	India)	
and	 volumetric	 flasks	 (type	 A)	 were	 obtained	 from	 Tarsons	
products	Pvt.	Ltd.	New	Delhi,	 India.	A	 liquid‐liquid	extraction	







degasser,	 and	 a	 SIL‐HTC	 auto	 sampler	 with	 a	 CTO‐10AS	 VP	
thermostat	 column	 oven	 maintained	 at	 35	 °C	 temperature.	
Kinetex	 5	 µm	 EVO	 C18,	 column	 (50	 mm	 in	 length,	 4.6	 mm	
internal	diameter,	and	5	µ	particle	size)	was	used	as	stationary	
phase.	 The	 analyte	 and	 internal	 standard	 were	 chromate‐
graphed	 isocratically	 using	 mobile	 phase	 consisting	 of	 a	
mixture	of	10	mM	ammonium	formate	pH	=	3.5	(adjusted	with	
formic	 acid),	 and	 acetonitrile	 (10:90,	 v:v).	 The	 flow	 rate	was	
set	 at	 0.6	mL/min.	 The	mobile	 phase	 flow	was	 controlled	 by	
using	 split,	 so	 that	 50%	of	 total	 flow	was	 injected	 to	 the	MS	
system.	
Mass	 spectrometric	 detection	 performed	 using	 API	 4000	
triple	 quadrupole	 instrument	 (MDS‐SCIEX,	 Concord,	 Ontario,	
Canada)	operated	in	a	multiple	reaction	mode	(MRM).	Source	




at	 5000	 V,	 entrance	 potential	 at	 10	 V,	 collision	 cell	 exit	
potential	 at	 4	 V,	 declustering	 potential	 at	 56	 V	 and	 collision	














Stock	 solution	 with	 concentration	 of	 approximately	 500	
µg/mL	was	prepared	 in	methanol	 for	 both	 analyte	 and	 ISTD.	
Serial	spiking	dilutions	of	analyte	were	prepared	in	the	linear	
range	of	1‐300	ng/mL	using	methanol	water	mixture	 (80:20,	
v:v)	 as	 diluent	 and	 1000	 ng/mL	 of	 levonorgestrel	 was	 also	
prepared	to	use	as	ISTD.	Quality	control	spiking	dilutions	were	







Calibration	 standards	 and	 QC	 samples	 were	 prepared	 in	
RIA	vial	 tubes	by	 spiking	at	2%	 (v:v)	of	 spiking	 solution	 into	
drug‐free	 human	 plasma	 containing	 K2EDTA	 as	 an	
anticoagulant.	Calibration	curve	samples	 (CC	1	to	CC	8)	were	
prepared	 across	 the	 concentrations	 range	 1‐300	 ng/mL.	 QC	
samples	 at	 5	 concentration	 levels	 prepared	 as	 follows,	 lower	
limit	of	quantification	QC	(LLOQ	QC),	1	ng/mL;	low	QC	(LQC),	3	
ng/mL;	medium	QC	 (MQC),	 126	 ng/mL;	 high	QC	 (HQC),	 228	
ng/mL	and	diluted	QC	 (DQC),	600	ng/mL.	All	 calibration	and	
QC	plasma	samples	prepared	in	RIA	vial	tubes	were	stored	in	a	
deep	 freezer	 at	 ‐70	 °C	 until	 analysis.	 Before	 sample	 prepa‐
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to	 a	 300	 µL	 plasma	 sample	 in	 a	 15	 mL	 RIA	 vial	 tube	 and	
vortexed	 for	10	s.	Then	add	300	µL	of	25	mM	sodium	carbo‐
nate	 solution	 and	 vortexed	 for	 10	 seconds.	 Add	 3	 mL	
extraction	 solvent	 (n‐hexane:	 Methyl	 tert‐butyl	 ether	 (50:50,	
v:v)	 and	 vortexed	 for	 10	 min	 at	 2000	 rpm.	 After	 agitation,	
samples	were	subjected	to	freeze	for	separating	the	extraction	
solvent.	The	separated	extraction	solvent	was	evaporated	 for	
20	 min	 under	 dry	 nitrogen	 gas	 at	 pressure	 of	 20	 psi.	 After	
evaporation	 the	 samples	 were	 reconstituted	 with	 200	 µL	 of	














cost	 effective	 method,	 levonorgestrel	 is	 selected	 as	 internal	
standard,	which	was	 found	 to	have	 almost	 similar	 behaviour	
(chemical	 structure	and	 ionisation)	 and	 co‐eluting	properties	
as	 analyte.	 Levonorgestrel	 also	 has	 similar	 extraction	
efficiency	in	optimized	conditions	and	because	of	its	negligible	







(ESI)	 source.	 It	 was	 found	 that	 positive‐ion	 mode	 exhibits	
greater	 sensitivity	 for	 analyte	 and	 internal	 standard.	 Tuning	
and	 optimization	 of	 compound	 parameters	 (Declustering	
potential;	 DP,	 Entrance	 potential;	 EP,	 Collision	 energy;	 CE,	
Collision	 cell	 exit	 potential;	 CXP)	 was	 done	 for	 selecting	 ion	
transitions	for	both	parent	and	product	ions	for	MRM.	Finally	
source	 parameters	 for	 multiple	 reactions	monitoring	 (MRM)	
were	 optimized	 by	 infusing	 analyte	 and	 ISTD	 along	 with	
mobile	phase.	
The	chromatographic	conditions	were	optimized	primarily	
on	 composition	 of	 mobile	 phase.	 Analyte	 and	 ISTD	 were	
injected	 initially	 using	 mobile	 phase	 consisting	 mixture	 of	
acetonitrile,	10	mM	ammonium	formate	70:30	(v:v)	on	Zorbax	
C18	 (5	 µm,	 50×4.6	mm,	 i.d.).	 The	 chromatographic	 retention	











Protein	 precipitation,	 LLE	 has	 been	 checked	 for	 sample	
preparation.	Protein	precipitation	is	simple	but	levonorgestrel	
shows	 matrix	 effect	 over	 80%.	 In	 consequence,	 LLE	 was	
chosen	 to	 prepare	 samples	 for	 benefit	 of	 specificity	 and	
cleanliness.	 Methyl	 tertiary	 butyl	 ether,	 diethyl	 ether,	 ethyl	
acetate‐hexane	 were	 attempted	 individually	 and	 also	 as	
solvent	mixtures.	 Finally	 n‐hexane:methyl	 tert‐butyl	 ether	 in	






Method	 validation	 for	 analysis	 of	 ulipristal	 acetate	 in	
human	plasma	has	been	carried	out	in	compliance	with	the	US‐
FDA	 and	 ANVISA	 resolution	 (Brazil)	 guidelines	 [9,10]	 as	 per	
method	validation	plan.	Results	were	 evaluated	 for	precision	
(CV	≤	15%;	LLOQ	and	LLOQ	QC:	CV	≤	20%)	and	accuracy	(back	
calculated	 concentrations	 within	 85‐115%;	 LLOQ	 and	
LLOQQC:	80‐120%	 compared	 to	 nominal	 concentrations).	 All	




15%)	 were	 within	 the	 acceptable	 limits.	 Prepared	 stock	









5%	 at	 retention	 time	 of	 analyte	 and	 internal	 standard	
respectively.	All	 the	glassware	used	 in	 the	study	was	washed	
with	 diluent	 and	 injected	 into	 the	 system	 with	 method	






potential	 interferences	 of	 endogenous	 compounds	 present	 in	
biological	 matrix	 or	 co‐eluting	 interferences	 at	 the	 retention	
time	of	the	analyte	and	ISTD.	Total	of	12	human	blank	plasma	
samples	were	 processed	 as	 per	 sample	 extraction	 procedure	
as	 follows:	8	normal,	2	 lipemic	and	2	heamolytic	plasma	 lots.	
No	interference	peaks	were	observed	at	the	retention	time	of	







The	 effect	 of	 the	 presence	 of	 endogenous	 matrix	
components	on	ulipristal	acetate	was	evaluated	in	10	different	
screened	 blank	 plasma	 lots	 (6	 normal,	 2	 lipemic	 and	 2	
hemolytic)	containing	K2EDTA	as	an	anticoagulant.	From	each	
plasma	lot	a	total	of	6	samples	(three	replicates	each	for	LQC	




lot.	 Samples	 were	 reconstituted	 with	 respective	 solutions	
(post	spiking,	one	LQC	and	one	HQC)	prepared	in	mobile	phase	
to	 get	 the	 equal	 concentration	 as	 extracted	 samples.	 Prepare	





factor	 for	analyte	 in	K2EDTA	were	0.98	and	6.30	 for	LQC	and	








MF	analyte	 MF	ISTD ISNMF MF	analyte MF	ISTD	 ISNMF
LOT‐1	 0.91	 0.92	 0.99	 0.94	 0.88	 1.07	
LOT‐2	 0.88	 0.95	 0.93	 0.88	 0.84	 1.05	
LOT‐3	 0.85	 0.91 0.93 0.92 0.89	 1.03
LOT‐4	 0.86	 0.92 0.93 0.93 0.96	 0.97
LOT‐5	 0.92	 0.98 0.94 0.94 0.89	 1.06
LOT‐6	 0.91	 0.86 1.06 0.92 0.95	 0.97
LOT‐7	Hemolytic	 0.92	 0.85 1.08 0.88 0.94	 0.94
LOT‐8	Hemolytic	 0.86	 0.88 0.98 0.86 0.82	 1.05
LOT‐9	Lipemic	 0.89	 0.94	 0.95	 0.92	 0.88	 1.05	
LOT‐10	Lipemic	 0.91	 0.85	 1.07	 0.92	 0.96	 0.96	
Mean	 0.9860 Mean 1.013
SD	(Standard	deviation)	 0.0618 SD 0.0491



















While	 infusing	 continues	 extracted	 solution	 from	 blank	
matrix,	 the	 aqueous	 solution	 of	 analyte	 at	 LOQ	 level	 was	







cell	 membrane	 are	 the	 major	 cause	 of	 matrix	 effect	 in	 bio	
analytical	 methods	 [11,12].	 Extracted	 blank	 sample	 was	
injected	using	MRM	(m/z	184	→	m/z	184),	the	most	commonly	
selected	MRM	 to	 check	 the	 typical	 phospholipids	 (2‐lyso	 and	
diradyl	phosphocholines)	 elution.	Further,	 analytical	 run	was	
extended	 to	 10	 min	 to	 check	 long	 runs	 and	 phospholipid	
elution	 [12].	 The	 chromatogram	 represents	 that	 there	 is	 no	
elution	 of	 phospholipids	 at	 the	 retention	 time	 of	 analyte	 and	
ISTD	 and	 also	 in	 continuous	 run	 which	 represents	 sample	





The	 measurable	 LLOQ	 is	 determined	 at	 1	 ng/mL	
concentration.	Prepared	and	processed	6	 replicates	of	 spiked	
LLOQ	plasma	 samples.	 The	Average	 signal	 to	noise	 ratio	was	
found	to	be	80.1.	The	precision	(%RSD	or	%CV)	and	accuracy	






Linearity	 was	 performed	 using	 eight	 calibration	 points	
(except	 standard	 blank	 and	 standard	 zero)	 across	 the	
calibration	range	of	1‐300	ng/mL	(1,	2,	5,	20,	80,	160,	240	and	
300	 ng/mL).	 Standard	 blank	 sample	 with	 addition	 of	 50	 µL	
diluent	 and	 standard	 zero	 sample	 with	 addition	 of	 50	 µL	 of	
ISTD	are	prepared	along	with	calibration	curve	samples.	Both	
samples	were	used	 to	 check	 the	 interferences	 at	 analyte	 and	
ISTD	 retention	 times.	 The	 observed	 interference	 at	 the	
retention	time	of	analyte	and	ISTD	is	not	more	than	20%	and	
5%,	 respectively.	 A	 linear	 regression	 analysis	 with	 weighing	
(1/x2)	 was	 used	 to	 determine	 slopes,	 intercepts,	 and	





The	 extraction	 recovery	 of	 the	 analyte	 and	 ISTD	 from	
human	 plasma	 was	 determined	 by	 comparing	 each	 six	
replicates	 of	 LQC,	 MQC	 and	 HQC	 of	 processed	 samples	 with	
that	 of	 respective	 post	 spiked	 samples.	 The	 recovery	 at	 LQC,	




3.1.3)	results	 in	variable	recoveries	 for	analyte	and	 ISTD,	but	
finally	 similar	 recovery	 for	 both	 analyte	 and	 ISTD	 were	
achieved	with	proposed	extraction	solvent	which	nullifies	the	

























LLOQQC	 1	 0.9±0.1	 7.0 94.2 1.0±0.1 6.3	 95.6
LQC	 3	 3.0±0.1	 3.9 98.6 3.0±0.1 4.0	 98.3
MQC	 126	 127.7±3.5	 2.7	 98.7	 126.4±5.5	 4.4	 99.7	
HQC	 228	 232.6±8.7	 3.7	 98.0	 232.4±7.3	 3.1	 98.1	
DQC	 600	 610.9±12.5	 2.1 98.2 607.9±14.0 2.3	 98.7
	
	
The	 very	 near	 recovery	 of	 analyte	 and	 ISTD	 in	 turn	
indicates	similar	behaviour	of	analyte	and	ISTD.	The	intensity	
of	 analyte	 and	 ISTD	 in	 presence	 and	 absence	 of	 biological	
matrix	 indicates	 congener	 behaviour	 and	 levonorgestrel	
suitability	as	 ISTD.	So,	 the	method	mimics	 the	characteristics	
of	 isotope	 labelled	 internal	 standard.	 Based	 on	 this,	 we	





It	 is	 evaluated	 by	 performing	 three	 different	 batches	 on	




concentrations	 (accuracy)	 and	 their	 reproducibility	 (preci‐
sion)	at	each	concentration	level	were	shown	in	Table	3.		
The	 intraday	 (average	 of	 12	 replicates)	 and	 inter‐day	
(average	of	18	replicates)	precision	(%CV)	was	less	than	7.0%	
and	 the	 accuracy	 was	 in	 the	 range	 of	 94.2	 to	 99.7%.	 The	
obtained	 result	 proves	 that	 the	 method	 was	 rugged	 and	
reproducible	 over	 the	 proposed	 analytical	 range.	 The	 repre‐
sentative	 chromatograms	 of	 blank	 plasma,	 Lower	 limit	 of	





























top	 stability,	 freeze	 and	 thaw	 stability,	 long	 term	 stability	 in	
matrix)	and	in	the	processed	samples	(Dry	extract	stability,	In‐
injector	 stability	 and	 re‐injection	 reproducibility)	 were	
assessed	as	a	part	of	method	validation.	For	all	stability	experi‐
ments,	 six	 replicates	 of	 LQC	 and	HQC	 stability	 samples	were	
processed	 and	 evaluated	 against	 freshly	prepared	 calibration	
curve.	 In	 case	 of	 long	 term	 stability	 experiments	 fresh	 stock	
weighing	 was	 done	 on	 the	 day	 of	 evaluation.	 Samples	 were	
injected	 as	 per	 method	 validation	 working	 plan.	 %Stability	






Stability	conditions	 Conc.	added	(ng/mL)	 Stability	(%)	 Precision	(%)	
Ambient	temperature	20.67	h	 3 99.3 2.3	
228 98.9 3.0	
Freeze	and	thaw	cycles	 3 99.1 3.9	
228 97.3 3.2	
Auto	sampler	at	5	°C	for	29	h	 3	 97.2	 5.1	
228	 97.9	 2.6	
Dry	extract	at	2‐8	°C	for	35.98	h	 3 99.0 3.3	
228	 98.0	 3.3	




The	 analyte	 was	 considered	 to	 be	 stable	 in	 the	 tested	
conditions	if	the	precision	and	accuracy	was	within	≤15%	and	














at	 2‐8	 °C	 after	 six	 days.	 The	 %	 stability	 was	 calculated	 by	
comparing	 mean	 response	 of	 six	 replicates	 of	 stability	 and	





During	 clinical	 trial	 process,	 investigators	may	 use	 some	
over	the	counter	medications	to	treat	unexpected	or	expected	
adverse	 effects	 like	 fever,	 nausea,	 vomiting	 etc.	 Therefore,	
selectivity	 and	 reproducibility	 of	 the	 analytical	 method	 was	
evaluated	 in	 presence	 of	 concomitant	 drugs	 by	 spiking	
respective	drug	dilutions	 in	 individual	blank	plasma	samples.	
Along	with	this	cocktail	mixture	of	concomitant	drug	dilution	
was	 prepared	 and	 spiked	 at	 LQC	 level.	 The	 concentration	 of	
concomitant	 medication	 drugs	 used	 approximately	 equal	 to	
their	 Cmax	 value.	 Prepared	 samples	 were	 subjected	 to	
extraction	 along	 with	 calibration	 curve	 and	 analysed.	 The	
precision	 and	 accuracy	 of	 LQC	 samples	 and	 observed	
interference	 from	blank	 samples	 at	 retention	 time	 of	 analyte	
and	ISTD	compared	to	low	standard	in	calibration	curve	were	
found	 to	 be	 within	 acceptable	 limits.	 The	 commonly	 used	





Stability	 of	 the	 analyte	 in	 whole	 human	 blood	 was	
evaluated	at	 room	temperature.	 Stability	 samples	at	LQC	and	
HQC	 level	 in	whole	human	blood	were	prepared	and	kept	on	
the	 working	 bench.	 Approximately	 after	 2	 hr.,	 comparison	





procedure	 and	 analysed.	 The	 percentage	 stability	 was	
calculated	by	comparing	the	mean	area	ratios	of	stability	and	







level	 (LQC,	 MQC,	 HQC)	 from	 six	 different	 plasma	 vacutainer	
sources	of	K2	EDTA	(Jindal	Bio	lab,	Bio	X,	JN	science	tech,	BD‐
Mumbai,	 SV	 Lab	 tech‐Hyderabad,	 Jai	 bro	 diagnostics‐Delhi),	




analysed	 against	 the	 calibration	 curve.	 The	 overall	 accuracy	
and	 precision	 at	 LQC	 95.8,	 8.4%,	 MQC	 101.2%,	 5.3%	 and	 at	
HQC	 were	 103,	 3.4%.	 The	 results	 of	 this	 experiment	 shown	
that	 the	 proposed	 method	 was	 suitable	 for	 quantification	 of	
ulipristal	 acetate	 in	 clinical	 samples	 by	 eliminating	 inter	
subject	biological	matrix	variation.	
The	total	number	of	control	samples	processed	was	more	
than	 the	 total	 expected	 sampling	 time	 points	 for	 human	
pharmacokinetics/bioequivalence	studies	of	ulipristal	acetate.	
The	expected	samples	were	considered	based	on	the	pharma‐
cokinetic	 data	 of	 ulipristal	 acetate	 [13].	 The	 control	 samples	
acceptance	 in	 extended	 precision	 and	 accuracy	 run	 indicates	





The	 variation	 in	 ISTD	 response	 will	 affect	 the	 unknown	
sample	concentrations.	ISTD	variation	was	calculated	for	each	













but	 it	will	 affect	 the	unknown	sample	concentration	by	more	
than	15%.	
To	know	ISTD	response	trend	in	overall	analytical	run,	the	
absolute	 deviation	 between	 the	 average	 areas	 analyte	 and	
ISTD	were	 calculated	 and	 the	 deviation	 is	 3.6%.	 The	 overall	
precision	for	ISTD	response	is	5.1%.	The	result	of	 ISTD	trend	





For	monitoring	 ulipristal	 acetate	 concentration	 in	human	
plasma,	 a	 specific,	 selective,	 fast,	 sensitive	 and	 accurate	 LC‐
MS/MS	method	was	developed	and	fully	validated	in	the	range	
of	1‐300	ng/mL.	The	validation	result	shows	that	the	method	
is	 repeatable,	 reproducible	 and	 robust.	 It	 can	 be	 applied	 for	
bioequivalence	 studies	 and	 larger	 Pharmacokinetic	 thera‐
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